EU drug legislation
This article was originally published in The Tan Sheet
Executive Summary
European Parliament adopts legislation allowing for an additional year of data exclusivity for OTC switch drugs April 30. Member states have until Oct. 30, 2005 to implement provisions of the new pharmaceutical legislation package. An additional year of data exclusivity for a new indication of a well-established substance also is enacted in the legislation, "provided that significant pre-clinical or clinical studies were carried out in relation to the new indication." The legislation initially allowed for three years of additional data exclusivity but was amended before its adoption (1"The Tan Sheet" Jan. 5, 2004, p. 9)...
You may also be interested in...
EU Revised Legislation Provides One-Year Exclusivity For OTC Switches
Rx-to-OTC switches in the European Union will be provided one year of data exclusivity, instead of the previously proposed three-year period, in a proposed amendment to EU pharmaceutical legislation recently approved by the European Parliament
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.